UCB S.A. (UCBJF)
Data as of October 19, 2026 · Biotechnology
Stockbruh grade: Challenging 0/5 metrics rated Sunny
What does UCB S.A. do?
UCB S.A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders. Its extensive portfolio of marketed products includes Cimzia, indicated for various inflammatory TNF-mediated diseases such as Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and axial spondyloarthritis (both radiographic and non-radiographic forms). For epilepsy management, UCB provides Vimpat, Keppra, and Briviact, alongside Nayzilam, a specialized nasal spray for acute rescue treatment of seizure clusters.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛅ Moderate | 5-year price performance |
| Profitability | ⛅ Moderate | Net margin & return on equity |
| Growth | ⛅ Moderate | Revenue & earnings trend |
| Earnings | ⛅ Moderate | EPS vs analyst expectations |
| Cash & Debt | ⛅ Moderate | Balance sheet strength |
| Price | $239.14 | Market Cap | — |
| Exchange | OTC | | |
Plain-English Analysis
What's it worth?
Performance has been moderate. Sign up free to see Stockbruh's full valuation analysis including price ratios and plain-English commentary.
How the business works
UCB S.A. is a prominent biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for individuals affected by neurological and immunological disorders. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Growth is mixed — some positive signals, but not consistent. Sign up free for Stockbruh's full growth breakdown.
What's ahead?
Earnings are mixed. Sign up free for the full earnings picture including EPS history and analyst forecasts.